Developer docs
API playgroundTry for free, no card

Search company profiles

Epiminder

Full company profile

uuid0009vmx

Namestring
Epiminder
Legal namestring
Epi-Minder Pty Ltd
Websiteurl
epiminder.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Epiminder is an Australian medical technology company that has developed and is commercializing the Minder System, the first and only FDA-authorized implantable continuous electroencephalogram (iCEM) monitoring device. Founded in 2018 as a research collaboration between the Bionics Institute, University of Melbourne, St Vincent's Hospital Melbourne, and Cochlear Limited, the company is headquartered in Melbourne and listed on the ASX under ticker EPI since December 2025. The company targets adults aged 18–75 with drug-resistant epilepsy — approximately 1.1 million US adults who have failed to achieve seizure freedom after two adequate anti-seizure medication trials.

The Minder System is a four-component integrated platform: a sub-scalp electrode implant placed behind the ear with multiple recording points enabling bilateral brain activity monitoring, an external Minder Wearable that receives wireless EEG transmissions via low-power Bluetooth, a Minder App for Android smartphones that uploads data to the cloud, and the Minder Cloud web portal where healthcare professionals can review and download patient EEG recordings. The architecture extends continuous monitoring from days (conventional scalp EEG) to multiple years — a UMPIRE study participant achieved a world-record five-year continuous EEG recording — and clinical data shows 88% of drug-resistant epilepsy patients received actionable clinical insights, including 23% with findings not possible with unilateral recording systems.

Epiminder's revenue model is anchored on one-time hardware sales of the Minder device at an assumed US$25,000 average selling price, supported by finalized Medicare reimbursement of US$27,700 per implant for 2026. New AMA Category III CPT codes effective January 2026 add a professional services revenue stream for implantation, interpretation, reporting, and remote monitoring, and a future subscription or SaaS model is planned for AI-enabled seizure forecasting software. Go-to-market is direct enterprise sales to leading US epilepsy centers and academic medical institutions, executed through a phased commercial rollout initiated in H2 2025 and supported by the DETECT clinical study generating real-world evidence across 19 participating sites including Mayo Clinic, University of Pennsylvania, Yale, Duke, Stanford, and Beth Israel Deaconess.

Short descriptiontext

Epiminder is an Australia-based medical technology company that developed the Minder System, the first FDA-authorized implantable continuous EEG monitoring device for adults with drug-resistant epilepsy. It serves neurologists and epilepsy centers via a four-component platform combining a sub-scalp implant, external wearable, smartphone app, and cloud portal enabling multi-year remote brain activity monitoring.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epilepsy monitoring device, implantable EEG system, continuous brain monitoring, neurological medical devices, epilepsy diagnostic technology
Industry2 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neurology Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Minder Device Sales
TypeHardware Sales
Description

One-time hardware sales of the Minder implantable device system to hospitals and epilepsy treatment centers. Medicare reimbursement established at US$27,700 per device with assumed average selling price of US$25,000. Revenue recognition expected to begin following US commercial launch.

epiminder.com
2Continuous EEG Monitoring Services
TypeProfessional Services
Description

AMA Category III CPT codes established for implantation, interpretation, reporting, and remote monitoring services for continuous EEG data. New codes effective January 2026 enable healthcare providers to bill for services related to reviewing and interpreting Minder patient data and remote monitoring.

epiminder.com
3Future Software Solutions
TypeSubscription Recurring
Description

Planned integrated software solutions including AI-enabled seizure forecasting to extend clinical impact of the Minder device. Subscription or software-as-a-service model anticipated for future offerings.

epiminder.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Minder Device - Medicare Reimbursement
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Medicare finalized 2026 reimbursement rate at US$27,700 per device, a 23% increase from initial ruling. This underpins assumed average selling price of US$25,000.

epiminder.com
2CPT Codes for Implantation and Monitoring Services
ModelOtherBilling cadencePay-as-you-go
Notes

AMA Category III CPT codes established for implantation procedure, interpretation, reporting and remote monitoring of continuous EEG data from sub-scalp monitoring systems. Codes effective January 2026.

epiminder.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Minder System
Description

Implantable continuous EEG monitoring (iCEM) system for epilepsy patients

epiminder.com
+4 more records
Core offering1 text field

Epiminder develops, manufactures, and commercializes the Minder System, a first-of-its-kind FDA-authorized implantable continuous EEG monitoring (iCEM) device for patients with drug-resistant epilepsy. The integrated system comprises a sub-scalp electrode implant, an external wearable receiver, a smartphone app, and a secure cloud platform enabling healthcare professionals to remotely monitor years of continuous brain activity data for clinical assessment and surgical planning.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 88% of patients in UMPIRE study received actionable clinical insights
+6 more records
Product overview1 text field

Epiminder offers the Minder® System, a comprehensive implantable continuous EEG monitoring (iCEM) solution. The system comprises four integrated components: the Minder Implant (sub-scalp electrode placed behind the ear for bilateral brain activity monitoring), Minder Wearable (external receiver worn by patient), Minder App (Android smartphone application for data transmission), and Minder Cloud (secure web portal for healthcare professionals). The company is also conducting the DETECT clinical study program, a prospective randomized controlled trial evaluating the system in US patients with drug-resistant epilepsy.

Product and service1 record
1Minder System
CategoryNeurology Medical Devices - Implantable EEG Monitoring
Description

The Minder System is an implantable continuous EEG monitoring (iCEM) system providing years-long continuous brain activity monitoring for patients aged 18-75 with drug-resistant epilepsy. The integrated system comprises the Minder Implant (sub-scalp electrode placed behind the ear with bilateral recording capability), Minder Wearable (external wireless receiver), Minder App (Android smartphone application for data transmission and seizure diary), and Minder Cloud (secure web portal for healthcare professional access). It is sold to hospitals and epilepsy treatment centers for use by neurologists and epileptologists managing patients with drug-resistant epilepsy.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-05-17
Description

Partnership with ACNS to help establish new Category III CPT codes for interpretation and reporting of continuous EEG data from sub-scalp implantable monitoring systems. ACNS worked with AMA to create codes enabling neurologists to bill for reviewing and interpreting Minder patient data.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2021-04-29
Description

Strategic collaboration to accelerate ultra-long term EEG monitoring through combined Minder implant and Seer Cloud technology. Seer provides advanced algorithms and data curation for seizure detection and forecasting. Seer has monitored nearly 6,000 Australians with at-home video-EEG-ECG equipment. Participated in $16m bridge financing round.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Internationally recognized independent medical research institute and co-founder of Epiminder. Led research on devices to alleviate symptoms of neurological disorders. Provided technological expertise in epilepsy seizure monitoring and bionic device development through research collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

World-leading research hospital and co-founder of Epiminder. Professor Mark Cook serves as neurologist and chair of medicine. Provided clinical research expertise and was site of initial Minder trials. Part of ACMD biomedical engineering research centre.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Global leader in higher education and co-founder of Epiminder. Professor Mark Cook serves as Chair of Medicine. Contributed research leadership and academic expertise to epilepsy monitoring technology development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Ceribell provides rapid-response EEG headbands and cloud-based seizure detection for hospitalized patients. While non-implantable, Ceribell competes in the EEG monitoring category and overlaps in epileptologist and neurology customer relationships.

TypeBroad incumbent
Description

Boston Scientific acquired the VNS franchise for epilepsy and has broad neuromodulation portfolio across multiple indications. The company is a broad incumbent in the device-based epilepsy treatment space that epileptologists already work with.

TypeBroad incumbent
Description

Boston Scientific's insertable cardiac monitor business (formerly Preventice BodyGuardian) offers implantable continuous monitoring with cloud analytics in cardiology. The technology and business model closely parallel Epiminder's Minder system applied to neurology.

TypeBroad incumbent
Description

Natus (now part of Natus Neuro) manufactures conventional scalp EEG systems, EMG, and intraoperative monitoring equipment used in epilepsy monitoring units. They are the incumbent EEG equipment supplier at many of the same centers Epiminder is targeting.

TypeEmerging player
Description

iRhythm's Zio long-term continuous cardiac monitor is a useful analog: a wearable + AI cloud platform enabling multi-day remote monitoring with reimbursement established and epileptologist/cardiology customer workflow parallels. Strong business-model comparison for the recurring-monitoring thesis.

TypeBroad incumbent
Description

Medtronic offers Deep Brain Stimulation (DBS) systems, including the Percept PC with BrainSense EEG capability, approved for epilepsy among other indications. As a global medtech incumbent, Medtronic has the resources to develop competitive continuous EEG neuro-monitoring offerings for the same epileptologist channel.

TypeDirect peer
Description

NeuroPace makes the RNS System, the only other FDA-approved implantable brain stimulation device for drug-resistant epilepsy. While RNS provides responsive neurostimulation rather than continuous EEG recording, both companies target the same patient population with implantable cranial devices and compete for the same epileptologist customers.

TypeDirect peer
Description

LivaNova markets Vagus Nerve Stimulation (VNS) Therapy for drug-resistant epilepsy. Epiminder's CEO previously ran LivaNova's neuromodulation division. Both compete for refractory epilepsy patients and epileptologist prescribing decisions.

TypeRegional player
Description

Compumedics is an Australia-based peer (like Epiminder) that manufactures EEG, sleep, and neurological monitoring equipment sold globally. It addresses the same customer base (epilepsy monitoring units, neurologists) with conventional scalp EEG rather than implantable solutions.

TypeDirect peer
Description

Seer Medical provides at-home video-EEG-ECG monitoring and cloud-based seizure analytics, and is both a strategic collaborator and bridge-round investor in Epiminder. Seer's non-invasive at-home offering addresses the same patient population with overlapping AI/seizure-detection technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Epiminder

Neurology Medical Devicesepiminder.com

Epiminder is an Australia-based medical technology company that developed the Minder System, the first FDA-authorized implantable continuous EEG monitoring device for adults with drug-resistant epilepsy. It serves neurologists and epilepsy centers via a four-component platform combining a sub-scalp implant, external wearable, smartphone app, and cloud portal enabling multi-year remote brain activity monitoring.

What Epiminder does

Epiminder is an Australian medical technology company that has developed and is commercializing the Minder System, the first and only FDA-authorized implantable continuous electroencephalogram (iCEM) monitoring device. Founded in 2018 as a research collaboration between the Bionics Institute, University of Melbourne, St Vincent's Hospital Melbourne, and Cochlear Limited, the company is headquartered in Melbourne and listed on the ASX under ticker EPI since December 2025. The company targets adults aged 18–75 with drug-resistant epilepsy — approximately 1.1 million US adults who have failed to achieve seizure freedom after two adequate anti-seizure medication trials.

The Minder System is a four-component integrated platform: a sub-scalp electrode implant placed behind the ear with multiple recording points enabling bilateral brain activity monitoring, an external Minder Wearable that receives wireless EEG transmissions via low-power Bluetooth, a Minder App for Android smartphones that uploads data to the cloud, and the Minder Cloud web portal where healthcare professionals can review and download patient EEG recordings. The architecture extends continuous monitoring from days (conventional scalp EEG) to multiple years — a UMPIRE study participant achieved a world-record five-year continuous EEG recording — and clinical data shows 88% of drug-resistant epilepsy patients received actionable clinical insights, including 23% with findings not possible with unilateral recording systems.

Epiminder's revenue model is anchored on one-time hardware sales of the Minder device at an assumed US$25,000 average selling price, supported by finalized Medicare reimbursement of US$27,700 per implant for 2026. New AMA Category III CPT codes effective January 2026 add a professional services revenue stream for implantation, interpretation, reporting, and remote monitoring, and a future subscription or SaaS model is planned for AI-enabled seizure forecasting software. Go-to-market is direct enterprise sales to leading US epilepsy centers and academic medical institutions, executed through a phased commercial rollout initiated in H2 2025 and supported by the DETECT clinical study generating real-world evidence across 19 participating sites including Mayo Clinic, University of Pennsylvania, Yale, Duke, Stanford, and Beth Israel Deaconess.

Epiminder firmographics

Firmographics
Name
Epiminder
Legal name
Epi-Minder Pty Ltd
Website
https://epiminder.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Epiminder is an Australia-based medical technology company that developed the Minder System, the first FDA-authorized implantable continuous EEG monitoring device for adults with drug-resistant epilepsy. It serves neurologists and epilepsy centers via a four-component platform combining a sub-scalp implant, external wearable, smartphone app, and cloud portal enabling multi-year remote brain activity monitoring.
Ownership category
akta.pro rank

Epiminder industry classification

Industry
Product category
Neurology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders

Keywords

  • Epilepsy monitoring device
  • Implantable EEG system
  • Continuous brain monitoring
  • Neurological medical devices
  • Epilepsy diagnostic technology

Where Epiminder is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Epiminder business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Minder Device Sales: One-time hardware sales of the Minder implantable device system to hospitals and epilepsy treatment centers. Medicare reimbursement established at US$27,700 per device with assumed average selling price of US$25,000. Revenue recognition expected to begin following US commercial launch.
  2. Continuous EEG Monitoring Services: AMA Category III CPT codes established for implantation, interpretation, reporting, and remote monitoring services for continuous EEG data. New codes effective January 2026 enable healthcare providers to bill for services related to reviewing and interpreting Minder patient data and remote monitoring.
  3. Future Software Solutions: Planned integrated software solutions including AI-enabled seizure forecasting to extend clinical impact of the Minder device. Subscription or software-as-a-service model anticipated for future offerings.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMinder Device - Medicare Reimbursement
OtherPay-as-you-goCPT Codes for Implantation and Monitoring Services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Epiminder product offering

Product offering

Core offering

Epiminder develops, manufactures, and commercializes the Minder System, a first-of-its-kind FDA-authorized implantable continuous EEG monitoring (iCEM) device for patients with drug-resistant epilepsy. The integrated system comprises a sub-scalp electrode implant, an external wearable receiver, a smartphone app, and a secure cloud platform enabling healthcare professionals to remotely monitor years of continuous brain activity data for clinical assessment and surgical planning.

Product overview

Epiminder offers the Minder® System, a comprehensive implantable continuous EEG monitoring (iCEM) solution. The system comprises four integrated components: the Minder Implant (sub-scalp electrode placed behind the ear for bilateral brain activity monitoring), Minder Wearable (external receiver worn by patient), Minder App (Android smartphone application for data transmission), and Minder Cloud (secure web portal for healthcare professionals). The company is also conducting the DETECT clinical study program, a prospective randomized controlled trial evaluating the system in US patients with drug-resistant epilepsy.

Differentiator

Problem solved

Functional benefit

Brands

  • Minder System: Implantable continuous EEG monitoring (iCEM) system for epilepsy patients
  • Minder Cloud
  • Minder App
  • DETECT Study
  • UMPIRE Study

Products and services

  • Minder System The Minder System is an implantable continuous EEG monitoring (iCEM) system providing years-long continuous brain activity monitoring for patients aged 18-75 with drug-resistant epilepsy. The integrated system comprises the Minder Implant (sub-scalp electrode placed behind the ear with bilateral recording capability), Minder Wearable (external wireless receiver), Minder App (Android smartphone application for data transmission and seizure diary), and Minder Cloud (secure web portal for healthcare professional access). It is sold to hospitals and epilepsy treatment centers for use by neurologists and epileptologists managing patients with drug-resistant epilepsy.

Quantifiable outcome

  • 88% of patients in UMPIRE study received actionable clinical insights
  • +6 more outcomes

Companies that use Epiminder

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Epiminder technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Epiminder partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic and core.

  • American Clinical Neurophysiology Society (ACNS)strategicStrategic or Co-development Partner · 17 May 2025Partnership with ACNS to help establish new Category III CPT codes for interpretation and reporting of continuous EEG data from sub-scalp implantable monitoring systems. ACNS worked with AMA to create codes enabling neurologists to bill for reviewing and interpreting Minder patient data.
  • Seer MedicalstrategicTechnology or Integration · 29 April 2021Strategic collaboration to accelerate ultra-long term EEG monitoring through combined Minder implant and Seer Cloud technology. Seer provides advanced algorithms and data curation for seizure detection and forecasting. Seer has monitored nearly 6,000 Australians with at-home video-EEG-ECG equipment. Participated in $16m bridge financing round.
  • Bionics InstitutecoreStrategic or Co-development Partner · 1 January 2018Internationally recognized independent medical research institute and co-founder of Epiminder. Led research on devices to alleviate symptoms of neurological disorders. Provided technological expertise in epilepsy seizure monitoring and bionic device development through research collaboration.
  • St Vincent's Hospital MelbournecoreStrategic or Co-development Partner · 1 January 2018World-leading research hospital and co-founder of Epiminder. Professor Mark Cook serves as neurologist and chair of medicine. Provided clinical research expertise and was site of initial Minder trials. Part of ACMD biomedical engineering research centre.
  • University of MelbournecoreStrategic or Co-development Partner · 1 January 2018Global leader in higher education and co-founder of Epiminder. Professor Mark Cook serves as Chair of Medicine. Contributed research leadership and academic expertise to epilepsy monitoring technology development.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Epiminder competitors and assessment

Company assessment

Emerging players

  • Ceribell: Ceribell provides rapid-response EEG headbands and cloud-based seizure detection for hospitalized patients. While non-implantable, Ceribell competes in the EEG monitoring category and overlaps in epileptologist and neurology customer relationships.
  • iRhythm Technologies: iRhythm's Zio long-term continuous cardiac monitor is a useful analog: a wearable + AI cloud platform enabling multi-day remote monitoring with reimbursement established and epileptologist/cardiology customer workflow parallels. Strong business-model comparison for the recurring-monitoring thesis.

Broad incumbents

  • Boston Scientific: Boston Scientific acquired the VNS franchise for epilepsy and has broad neuromodulation portfolio across multiple indications. The company is a broad incumbent in the device-based epilepsy treatment space that epileptologists already work with.
  • Preventice Solutions (Boston Scientific): Boston Scientific's insertable cardiac monitor business (formerly Preventice BodyGuardian) offers implantable continuous monitoring with cloud analytics in cardiology. The technology and business model closely parallel Epiminder's Minder system applied to neurology.
  • Natus Medical: Natus (now part of Natus Neuro) manufactures conventional scalp EEG systems, EMG, and intraoperative monitoring equipment used in epilepsy monitoring units. They are the incumbent EEG equipment supplier at many of the same centers Epiminder is targeting.
  • Medtronic: Medtronic offers Deep Brain Stimulation (DBS) systems, including the Percept PC with BrainSense EEG capability, approved for epilepsy among other indications. As a global medtech incumbent, Medtronic has the resources to develop competitive continuous EEG neuro-monitoring offerings for the same epileptologist channel.

Direct peers

  • NeuroPace: NeuroPace makes the RNS System, the only other FDA-approved implantable brain stimulation device for drug-resistant epilepsy. While RNS provides responsive neurostimulation rather than continuous EEG recording, both companies target the same patient population with implantable cranial devices and compete for the same epileptologist customers.
  • LivaNova: LivaNova markets Vagus Nerve Stimulation (VNS) Therapy for drug-resistant epilepsy. Epiminder's CEO previously ran LivaNova's neuromodulation division. Both compete for refractory epilepsy patients and epileptologist prescribing decisions.
  • Seer Medical: Seer Medical provides at-home video-EEG-ECG monitoring and cloud-based seizure analytics, and is both a strategic collaborator and bridge-round investor in Epiminder. Seer's non-invasive at-home offering addresses the same patient population with overlapping AI/seizure-detection technology.

Regional players

  • Compumedics: Compumedics is an Australia-based peer (like Epiminder) that manufactures EEG, sleep, and neurological monitoring equipment sold globally. It addresses the same customer base (epilepsy monitoring units, neurologists) with conventional scalp EEG rather than implantable solutions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Epiminder social profiles

Digital presence

Epiminder compliance and trust

Trust signal

Compliance4 records

Epiminder financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Epiminder leadership team

Management profile

Number of profiles

Profiles14 records

Epiminder subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Epiminder funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Epiminder M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Epiminder

What does Epiminder do?

Epiminder develops, manufactures, and commercializes the Minder System, a first-of-its-kind FDA-authorized implantable continuous EEG monitoring (iCEM) device for patients with drug-resistant epilepsy. The integrated system comprises a sub-scalp electrode implant, an external wearable receiver, a smartphone app, and a secure cloud platform enabling healthcare professionals to remotely monitor years of continuous brain activity data for clinical assessment and surgical planning.

Is Epiminder a public or private company?

Epiminder is a public company. It is classified as public and is currently operating.

When was Epiminder founded?

Epiminder was founded in 2018. It employs 11 to 50 people.

Where is Epiminder based?

Epiminder is headquartered in Melbourne, Australia, in the Oceania region.

How does Epiminder make money?

Three revenue lines are on record. Minder Device Sales are the primary driver. The others are continuous EEG Monitoring Services and future Software Solutions.

Who are Epiminder's main competitors?

Emerging players on record are Ceribell and iRhythm Technologies. Broad incumbents are Boston Scientific, Preventice Solutions (Boston Scientific), Natus Medical and Medtronic. Direct peers are NeuroPace, LivaNova and Seer Medical. Compumedics is listed as a regional player.

Does Epiminder have an API?

No public API is recorded for Epiminder.

What industry is Epiminder in?

Epiminder's product category is Neurology Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLAKAIAB, Epilepsy & Seizure Disorders. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestEpiminder's chairman 'lifted his holding' by A$4,830 in his wife's name — a disclosure footnote, not a signalEpiminder chairman Philip Binns' wife bought 14,000 shares at A$0.345 on 1 September 2026, increasing her holding from 18,587 to 32,587. The A$4,830 purchase is a small stake in a pre-revenue company with A$89 million in IPO cash and no revenue. The disclosure is a governance footnote, not a signal.Simply Wall StHere's Why We're Watching Epiminder's (ASX:EPI) Cash Burn SituationEpiminder (ASX:EPI) had AU$89 million in cash as of December 2025 against AU$47 million in annual cash burn, providing approximately 23 months of runway, according to financial analysis by Simply Wall St. The company's cash burn increased by 203% year-over-year, with the AU$47 million burn representing 69% of its AU$68 million market capitalisation, raising concerns about potential extreme shareholder dilution if additional funding is required.Finance News NetworkASX IPO Market Faces Mixed StartThe ASX IPO market had a subdued start to the year, with Unity Metals debuting at 20 cents per share and closing flat after briefly touching 22 cents. Several late-2025 IPOs are trading below their debut prices, including Carma (down from $2.70 to below $2.10), Epiminder (below $1 from its $1.50 debut), and Saluda Medical (shares more than halving on their first day). Fund managers remain optimistic that favorable inflation data could revive IPO activity, with companies including Firmus Technologies, Home Furniture Group, I-MED, and Greencross expected to list in 2026.FrostAt-home Diagnostics 2032 & Beyond: Where Growth Meets AccessibilityFrost & Sullivan reports that the at-home diagnostics sector is undergoing rapid transformation driven by AI integration, workforce shortages, and pandemic-era regulatory shifts. The analysis highlights emerging technologies such as silicon photonics and nanotechnology biosensors to expand decentralized healthcare capabilities by 2032. Key industry players including Canary Speech, Epi Minder, and 52 North Health are cited for their specific innovations in vocal biomarkers, EEG implants, and portable diagnostic tests.Stocks Down UnderEpiminder Debuts on ASX With FDA-Approved Epilepsy DeviceEpiminder, a Melbourne-based medtech company, debuted on the ASX after raising $125 million, and plans to launch its FDA-approved Minder epilepsy monitoring device in the US next year. The device extends the monitoring window for epilepsy patients, offering significant clinical improvements and a large market opportunity. The company aims to demonstrate clinical utility through a US clinical trial to facilitate commercial success.Startup DailyCochlear-backed Epiminder hits the ASX – and plungesMedtech company Epiminder launched its IPO on the ASX at $1.50 per share, raising $125 million with a market capitalization of approximately $325 million to fund its US commercial rollout. The stock declined over 10% in its debut due to an ASX technical glitch and continued falling in subsequent trading. Cochlear, Epiminder's largest shareholder, increased its stake to 36%, while the company also secured favorable US Medicare reimbursement rates for its epilepsy monitoring device.SmartCompanyEpilepsy device-maker Epiminder lists on the ASX with $290 million market capMedical device company Epiminder Limited listed on the Australian Securities Exchange on December 1, 2025, with a market capitalization of $290 million. The IPO raised $125 million in primary capital to fund the company's commercial expansion. Epiminder plans to launch its GO Minder epilepsy monitoring system in the United States during the first half of 2026.YahooFDA Grants Authorisation for Minder®, the First and Only Implantable Continuous EEG Monitor Approved in USThe FDA granted De Novo authorization for Minder, an implantable continuous EEG monitor for epilepsy, creating a new device classification. Epiminder plans a US launch in H2 2025, with the device validated by the UMPIRE trial. The company aims to develop AI-enabled software for seizure forecasting.LsjAdvancements in neurotechnology and what it means for lawyersNeuralink will commence human trials within six months, while Synchron has been conducting trials since July 2022. Dr Allan McCay noted Australian companies like Epiminder and EMOTIV could be clients, and lawyers must advise on TGA and FDA approvals. He also highlighted potential criminal law issues, such as proving mental acts as actus reus.